| 1 |
34101295 | Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma. | 2021 Oct |
1 |
| 2 |
27105527 | Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src. | 2016 May 31 |
9 |
| 3 |
28074043 | Correction: Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src. | 2016 Nov 22 |
2 |
| 4 |
25199623 | Suberoylanilide hydroxamic acid enhances the antitumor activity of oxaliplatin by reversing the oxaliplatin‑induced Src activation in gastric cancer cells. | 2014 Nov |
5 |
| 5 |
25208577 | Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer. | 2014 Sep 10 |
5 |
| 6 |
23712327 | Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells. | 2013 Jul |
8 |
| 7 |
21737505 | Targeting SRC in mucinous ovarian carcinoma. | 2011 Aug 15 |
2 |
| 8 |
19383922 | Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. | 2009 May 1 |
9 |
| 9 |
18790786 | Effect of chemotherapeutic stress on induction of vascular endothelial growth factor family members and receptors in human colorectal cancer cells. | 2008 Sep |
3 |
| 10 |
15326164 | Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis. | 2004 Oct 29 |
4 |